Kkr & Co. Inc.
—- Market cap
- $96.70B
- Debt
- +$328.51B
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 23% equity / 77% debt
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: KKR stock price at discount vs ALNY $107.73 current versus $301.60 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ALNY's multiple
Implied fair value · at KKR's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Value edge
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: KKR FY 2025 (ended Dec 31, 2025) · ALNY FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 23% equity / 77% debt
Capital structure 90% equity / 10% debt · EV / Revenue 10.25x · EV / EBITDA 63.81x
KKR carries the larger enterprise value at $425.21B against $38.07B; ALNY trades on the lower EV / Revenue multiple (10.25x vs 21.85x); ALNY on the lower EV / EBITDA (63.81x vs 71.04x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
KKR & CO. INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
ALNYLAM PHARMACEUTICALS, INC. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
10.63x
5.22x
Net debt / EBITDA
Leverage against operating earnings
—
4.13x
Cash and equivalents
Liquid reserves on the balance sheet
—
$1.66B
Total debt
Interest-bearing obligations outstanding
$328.51B
$4.12B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
BlackRock, Inc.
KKR vs BLK
Blackstone Inc.
KKR vs BX
Apollo Global Management, Inc.
KKR vs APO
Carlyle Group Inc.
KKR vs CG
Ares Management Corp
KKR vs ARES
Moderna, Inc.
KKR vs MRNA
Sarepta Therapeutics, Inc.
KKR vs SRPT
VERTEX PHARMACEUTICALS INC / MA
KKR vs VRTX
BioNTech SE
KKR vs BNTX
ACADIA PHARMACEUTICALS INC
KKR vs ACAD
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.